Skip to content
Sharism- Lifestyle
Author:
Hopstem Biotechnology Inc.
Hopstem Receives U.S. FDA IND Clearance and Fast Track designations for hNPC01 in Hemorrhagic Stroke and Traumatic Brain Injury-Expanding Clinical Development Across Three Major Brain Injury Indications
July 29, 2026
Hopstem hNPC01 Cell Injection Earns FDA RMAT Designation for Chronic Stroke Therapy
June 3, 2026